This article is part of the Topical Collection on Leukemia
Strict criteria for when to stop tyrosine kinase inhibitor (TKI) therapy in clinical practice are not easily defined without an agreement on what probability of achieving a treatment-free remission (TFR) constitutes a medically acceptable standard and consideration of the potential medical risks of continued TKI therapy and/or patient preferences. Patients in sustained deep molecular response (DMR) have no significant chronic myelogenous leukemia-related risk of progression and death, and thus, safety is of paramount importance. Patients with prior history of advanced disease, additional chromosomal abnormalities (ACA), atypical transcripts, TKI resistance, high Sokal score, or who cannot be relied upon to come for regular molecular monitoring should generally be excluded from TKI cessation in clinical practice. Similarly, stopping TKIs should not be attempted without the availability of standardized BCR-ABL1 testing with a sensitivity of at least MR4.5 and a turnaround time of less than 4 weeks. Prior TKI therapy of 5 years and stable MR4.0 of 2 years or more constitutes reasonable minimal criteria for stopping TKIs with approximately a 50% chance of success. The risk of morbidity with continued TKI therapy and patient preferences need to be considered to determine to what extent these minimal criteria should be exceeded and at what threshold to re-initiate therapy whether on the loss of major molecular response or at a lower molecular endpoint.
NCCN Clinical practice guidelines in oncology. Chronic Myeloid Leukemia Version I2018 - July 26, 2017.
Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32(5):424–30. CrossRefPubMed
Takahashi N, Tauchi T, Kitamura K, Miyamura K, Saburi Y, Hatta Y, et al. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. Int J Hematol. 2017; https://doi.org/10.1007/s12185-017-2334-x.
Thielen N, van der Holt B, Cornelissen JJ, Verhoef GE, Gussinklo T, Biemond BJ, et al. Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). Eur J Cancer. 2013;49(15):3242–6. CrossRefPubMed
Atallah E, Schiffer CA, Radich JP, Weinfurt K, Larson RA, Oehller V, et al. Results from the U.S. Life after Stopping TKIs (LAST) Study. 59th ASH Annual Meeting; Atlanta, GA: Blood. 2017; 130, A2903.
Clark R, Polydoros F, Apperley J, Pocock C, Smith G, Byrne J, et al. Initial reduction of therapy before complete withdrawal improves the chance of successful treatment discontinuation in chronic myeloid leukaemia (CML): year 2 results in the British DESTINY study. 22nd EHA Congress; Madrid, Spain: Haematologica. 2017;102, S423.
Hughes T, Boquimpani C, Takahashi N, Benyamini N, Clementino NC, Shuvaey V, et al. Durable treatment-free remission (TFR) after stopping second-line nilotinib (NIL) in patients (PTS) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTOP 96-wk update. 22nd EHA Congress; Madrid, Spain: Haematologica. 2017;102, P257.
Kadowaki N, Kawaguchi T, Kuroda J, Nakamae H, Matsumura I, Miyamoto T, et al. Discontinuation of nilotinib in patients with chronic myeloid leukemia who have maintained deep molecular responses for at least 2 years: a multicenter phase 2 stop nilotinib (Nilst) trial. 58th ASH Meeting; San Diego, CA: Blood. 2016;128, A790.
Kim D, Bence-Bruckler I, Forrest DL, Savoie L, Couban S, Busque L, et al. Interim results of the Canadian Tyrosine Kinase Inhibitor Discontinuation trial for 2nd attempt of treatment free remission: treatment free remission accomplished by dasatinib (TRAD). 59th ASH Annual Meeting; Atlanta, GA: Blood. 2017;130, A1622.
Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, et al. Discontinuation of dasatinib after deep molecular response for over 2 years in patients with chronic myelogenous leukemia and the unique profiles of lymphocyte subsets for successful discontinuation: a prospective, multicenter Japanese trial (D-STOP Trial). 58th ASH Meeting; San Diego, CA: Blood. 2016;128 A791.
Matsuki E, Sakurai M, Karigane D, Kasahara H, Kikuchi T, Shimizu T, et al. Second attempt to discontinue TKI in CML patients who have sustained CMR for over 2 years is rarely successful even with the use of second generation TKIs. 58th ASH Annual Meeting; San Diego, CA: Blood. 2016;128, A1887.
Richter J, Mahon FX, Guilhot J, Hjorth-Hansen H, Almedia A, Janssen JJ, et al. Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: Results of the EURO-SKI trial. 21st EHA Congress; Copenhagen, Denmark: Haematologica. 2016;101, S145.
Ross D, Massri T, Gómez Casares MT, Hellman A, Stentoft J, Conneally E, et al. Durable treatment-free remission (TFR) following frontline nilotinib (NIL) in patients (PTS) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom 96-wk update. 22nd Congress of EHA; Madrid, Spain: Haematologica. 2017;102, P601.
Shah NP, Gutiérrez VG, Jiménez-Velasco A, Larson SM, Saussele S, Rea D, et al. Dasatinib discontinuation in patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) and stable deep molecular response (DASFREE). 59th ASH Annual Meeting; Atlanta, GA: Blood. 2017;120 A314.
Takahashi N, Nakaseko C, Nishiwaki K, Wakita H. Two-year consolidation by nilotinib is associated with successful treatment free remission in chronic myeloid leukemia with MR4.5: subgroup analysis from STAT2 trial in Japan. 58th ASH Annual Meeting; San Diego, CA: Blood. 2016;128 A1889.
Fava C, Rege-Carmbrin G, Dogliotti I, Cerrano M, Berchialla P, Rosti G, et al. Observational study of CML Italian patients who discontinued TKIs. 59th ASH Annual Meeting; Atlanta, GA: Blood. 2017;130, A1616.
Clark RE, Polydoros F, Apperley JF, Milojkovic D, Pocock C, Smith G, et al. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematol. 2017;4(7):e310–e6. https://doi.org/10.1016/S2352-3026(17)30066-2. CrossRefPubMed
Boquimpani CM, Szczudlo T, Mendelson E, Benjamin K, Masszi T. Attitudes and perceptions of patients with chronic myeloid leukemia in chronic phase (CML-CP) toward treatment-free remission (TFR). 56th ASH Annual Meeting; San Francisco, CA: Blood. 2014;4547, A4547.
Goldberg S, Hamarman S. Patients with chronic myelogenous leukemia may not want to discontinue tyrosine kinase inhibitor therapy. 57th ASH Annual Meeting; Orlando, FL: Blood. 2015;126, A1584.
Mahon FX, Richter J, Guilhot J, Muller MC, Dietz CT, Porka K, et al. Interim analysis of a pan European stop tyrosine kinase inhibitor trial in chronic myeloid leukemia: The EURO-SKI study. 56th ASH Annual Meeting; San Francisco, CA: Blood. 2014;124, A151.
Saussele S, Richter J, Guilhot J, Hjorth-Hansen H, de Almeida AM, Janssen JJWM, et al. Duration of deep molecular response has most impact on the success of cessation of tyrosine kinase inhibitor treatment in chronic myeloid leukemia—results from the EURO-SKI Trial. 59th ASH Annual Meeting; Atlanta, GA: Blood. 2017;130, A313.
Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029–35. CrossRefPubMed
Rea D, Cayuela JM, Dulucq S, Etienne G. Molecular responses after switching from a standard-dose twice-daily nilotinib regimen to a reduced-dose once-daily schedule in patients with chronic myeloid leukemia: a real life observational study (NILO-RED). 59th ASH Annual Meeting; Atlanta, GA: Blood. 2017;130, A318.
Kota VK, Kong JH, Arellano M, El Rassi F, Gaddh M, Heffner LT, et al. Outcomes of newly diagnosed chronic phase chronic myeloid leukemia following an elective switch from second-generation tyrosine kinase inhibitor to imatinib. Clin Lymphoma Myeloma Leuk. 2017;17(12):e71–e3. https://doi.org/10.1016/j.clml.2017.09.004. CrossRefPubMed
- When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
MD Pierre Laneuville
- Springer US
Neu im Fachgebiet Onkologie
Mail Icon II